Development of digital twins as complex biomarkers for ERK signaling therapy through integration of pharmacogenomic data and comprehensive analysis of ERK and alternative signaling pathway dynamics
| Reference number | |
| Coordinator | Uppsala universitet - Uppsala universitet Inst f farmaceutisk biovetenskap |
| Funding from Vinnova | SEK 2 829 060 |
| Project duration | January 2026 - December 2028 |
| Status | Ongoing |
| Venture | European partnership for Personalised Medicine |
| Call | International collaboration in pharmacogenomics in personalised medicine |
Purpose and goal
The purpose is to develop digital twins as complex biomarkers for personalized cancer treatment in cases of dysregulated ERK signaling. The objective is to integrate pharmacogenomics, multi-omics, and phenotypic data from patient-proximal models and clinical cohorts to predict treatment response, identify effective drug combinations, and support clinical therapy decisions.
Expected effects and result
The project is expected to deliver a validated digital twin platform that functions as a complex biomarker for precision cancer medicine. The results include improved prediction of treatment response, identification of effective drug combinations, and reduced exposure to ineffective therapies. In the long term, the project will contribute to better patient outcomes, more efficient clinical decision-making, and reduced healthcare costs.
Planned approach and implementation
The project will be carried out in three integrated stages. First, drug responses will be mapped in patient-derived organoids using phenotypic cell profiling and proteomics. These data will then be integrated with genomic and transcriptomic information to develop mechanistic digital twins. Finally, the models will be validated using clinical data and implemented in molecular tumor boards to support personalized therapy decisions.